HUM-234

HUM-234 is a **synthetic cannabigerol derivative** being developed from research originating at Hebrew University of Jerusalem as a **small molecule cannabinoid receptor modulator** for metabolic and inflammatory diseases. Preclinical studies describe HUM-234 as an anti-inflammatory, analgesic, and anti-obesity agent that prevented weight gain in high-fat diet mouse models, reduced hepatic steatosis, and lowered serum liver enzymes such as ALT and AST. It is synthesized from monomethoxy cannabigerol and is related to HUM-233, described as its maleate salt form, and to HUM-223. The program appears to remain in **preclinical development**, with proposed applications including obesity and inflammatory conditions.